Lonza to expand ADC manufacturing capacity
| By Gerald Ondrey
Lonza (Basel, Switzerland; www.lonza.com) plans to invest CHF14 million (about $15 million) to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing…